BLRX - התחייבויות לטווח ארוך להון BioLineRx Ltd.

BioLineRx Ltd. (BLRX) is scaling its business by patenting innovations for subsequent licensing to pharma behemoths. The company is currently generating a stable cash flow from a new oncology drug, supported by investments. A key advantage is the FDA approval of Aphexda for stem cell mobilization. This chart provided by GURU.Markets shows that the long-term debt-to-equity ratio is currently around 0.24.

This metric measures the share of long-term liabilities within the equity structure, determining the business's financial stability amid rising interest rates. It is critical for investors to maintain a balance between minimizing bankruptcy risks and maximizing return on assets. By analyzing the trend of long-term debt relative to equity, one can quickly assess a company's margin of safety. For BioLineRx Ltd. (BLRX), a low debt load is confirmed by a stable cash flow. The commercialization of the stem cell mobilization drug strengthens liquidity, reducing reliance on external borrowings.